drugset
Drugs / Sofosbuvir-velpatasvir
last change Aug 2019 re-read 3 minutes ago

Sofosbuvir-velpatasvir

also known as SOF/VEL
Developed for
chronic hepatitis C virus infection
Investigated by
Gilead Sciences

Trials 1

today NCT02346721 · Ph 3
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02346721 Feb 2015 → Mar 2016 chronic hepatitis C virus infection Gilead Sciences Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2017-01-20 Gilead Sciences European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) gilead.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Sofosbuvir-velpatasvir “Sofosbuvir-velpatasvir is approved for the treatment of chronic hepatitis C virus (HCV) infection.” PMID 31216086 ↗ Aug 2019
Known as SOF/VEL “The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) in participants with chronic...” NCT02346721 ↗
Route Oral “400/100 mg tablet administered orally once daily” NCT02346721 ↗